Lys-MTXcleavable- (OtBu) significantly reduces tumor growth in HT1080 tumor bearing mice[1].
The protection of the α-carboxyl group of methotrexate may be used to improve the circulatory half-life and reduce the liver accumulation of similar MTX-conjugated dendrimers, while still retaining antitumor activity in vivo[1].
| Animal Model: | Female, Balb/c nu/nu, 6 weeks (bearing HT1080 cells)[1] |
| Dosage: | 30 mg/kg |
| Administration: | Once per week for 2 weeks |
| Result: | Showed a significant (63%) reduction in tumor size on day 12.
|
